S&P Futures
3,986.75 +21.00 (+0.53%) Dow Futures
33,930.00 +127.00 (+0.38%) Nasdaq Futures
11,725.50 +80.00 (+0.69%) Russell 2000 Futures
1,827.10 +7.40 (+0.41%) Crude Oil
71.89 +0.43 (+0.60%) Gold
1,812.60 +11.10 (+0.62%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 36.88 |
| Open | 36.36 |
| Bid | 36.24 x 2200 |
| Ask | 36.27 x 3100 |
| Day's Range | 36.31 - 36.99 |
| 52 Week Range | 28.47 - 46.97 |
| Volume | |
| Avg. Volume | 6,705,671 |
| Market Cap | 74.924B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 12.71 |
| EPS (TTM) | 2.67 |
| Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
| Forward Dividend & Yield | 2.21 (6.75%) |
| Ex-Dividend Date | Aug 18, 2022 |
| 1y Target Est | 44.32 |
- Reuters
NEWSMAKER-Audacious BlackRock challenge is Bluebell's David vs Goliath playbook
Bluebell Capital Partners' attempt to oust BlackRock Inc CEO Larry Fink represents the small activist hedge fund's boldest bet that its punch-above-weight strategy could deliver a financial win, even if its push for changes faces long odds. In the three years since its launch, Bluebell has challenged the policies and executives of some of the world's biggest companies, including GSK Plc, Glencore Plc, Vivendi SE and Danone SA, while owning very small stakes. The major prize Bluebell has so far scored was at Danone, where it helped oust a chief executive.
- MarketWatch
Get ready for a ‘confusing’ respiratory illness season
There are currently higher-than-normal levels of RSV and the flu in the U.S. At the same time, the number of new COVID-19 infections is rising.
- Benzinga
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate (ORR) and the key secondary endpoint of median progression-free survival (mPFS). The ORR was 46% (n=56/12
- Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer SymposiumCNW Group
- PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022Business Wire
